by jtcir-auto | Feb 26, 2024 | Press Releases
ISS states in its Aeterna Zentaris FOR recommendation that “on balance, the deal has strong strategic merit, third party solicitation was unable to generate any other actionable proposals, and governance conflicts appear to have been reasonably...
by jtcir-auto | Feb 15, 2024 | Press Releases
Aeterna Zentaris Board recommends shareholders vote FOR all resolutions, to create a diversified biopharmaceutical company with a compelling value propositionMore information and materials available at www.AEZSmerger.comShareholders with questions or who require...
by jtcir-auto | Feb 15, 2024 | Press Releases
Aeterna Zentaris Board recommends shareholders vote FOR all resolutions, to create a diversified biopharmaceutical company with a compelling value propositionMore information and materials available at www.AEZSmerger.comShareholders with questions or who require...
by jtcir-auto | Dec 14, 2023 | Press Releases
TORONTO and EDMONTON, Dec. 14, 2023 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna”) and Ceapro Inc. (TSXV: CZO) (OTCQX: CRPOF) (“Ceapro”), two innovative biopharmaceutical development companies, today...
by jtcir-auto | Dec 14, 2023 | Press Releases
TORONTO and EDMONTON, Dec. 14, 2023 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna”) and Ceapro Inc. (TSXV: CZO) (OTCQX: CRPOF) (“Ceapro”), two innovative biopharmaceutical development companies, today...
by jtcir-auto | Nov 9, 2023 | Press Releases
– Launch of Ghryvelin™ in a number of key countries in the European Economic Area – Approval of Macrilen® in South Korea in September – Ended the quarter with $38.8 million in cash, expected to fund operations and advancement of priority...